
Ivabradine approval timeline
• 2005 approved in EU for angina
• 2012 approved in EU for heart failure
• 2015 approved in US for heart failure
to reduce the risk for hospitalization for worsening heart failure in patients with
stable, symptomatic chronic heart failure with LVEF ≤35%, who are in sinus rhythm
with a resting heart rate of ≥70 beats per minute (bpm) and are taking maximally
tolerated doses of beta-blockers or have a contraindication to beta-blockers.